Monoclonal antibodyFDA-approvedSecond-line
Erbitux
Generic name: cetuximab
How it works
Blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from growing and dividing.
Cancer types
Colorectal Cancer— EGFR-expressing
Lung Cancer— Wild-type EGFR
Efficacy
Studies show that Erbitux improves progression-free survival in patients with metastatic colorectal cancer who have failed prior chemotherapy.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Adagrasib in Combination with Cetuximab and Irinotecan for Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Testing Fruquintinib and Cetuximab-beta for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Metastatic Colorectal Cancer with KRAS G12C Mutations | Colorectal Cancer | phase-1/2 | — | Source → |
| Testing New Combination Therapy for Advanced Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Testing VS-7375 in Pancreatic Cancer Patients with KRAS G12D Mutation | Pancreatic Cancer | phase-2 | — | Source → |
| Testing a New Treatment for Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Study of a New Treatment for Advanced Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Study of Combination Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing IBI351 with Cetuximab in Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a New Medicine for Advanced Solid Tumors with KRAS Mutations | Lung Cancer | phase-1 | — | Source → |
| Combining Treatments for Lung Cancer | Lung Cancer | lab-study | Response rates of 41% and 49% and median progression-free survival of 6.3 and 9.7 months. | Source → |
| New Treatment Option for Chinese Patients with Aggressive Colorectal Cancer | Colorectal Cancer | phase-2 | The Doublet arm demonstrated superior progression-free survival of 4.2 months vs. 2.5 months in the Control arm. | Source → |
| Succinate Helps Cancer Cells Resist Treatment | Colorectal Cancer | lab-study | — | Source → |
| NK Cells Show Promise Against Solid Tumors in Lab Experiments | Lung Cancer | lab-study | — | Source → |
| Butyrate May Reduce Effectiveness of Colorectal Cancer Treatment | Colorectal Cancer | lab-study | — | Source → |
| Machine Learning Predicts Cancer Treatment Outcomes | Colorectal Cancer | phase-3 | Higher toxicity clusters were associated with improved overall survival and progression-free survival outcomes (adjusted hazard ratios ranging from 2.21 to 4.36) and higher CET concentrations (p = .003). | Source → |
| RAS Mutations in Blood Linked to Poorer Outcomes in Colorectal Cancer | Colorectal Cancer | phase-2 | The presence of ctDNA RAS mutations at any time point was significantly associated with poorer progression-free survival (adjusted HR = 2.24, P = .02). | Source → |
| Woman with Advanced Colon Cancer Treated with Chemotherapy | Colorectal Cancer | observational | — | Source → |
| Rare Cancer Complication Found in Patient with BRAF Mutated Colon Cancer | Colorectal Cancer | observational | — | Source → |
| Comparing Two Cancer Treatments in Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | There was no significant difference in median overall survival between treatment groups (9.1 months vs 10.1 months). | Source → |
| Combining Chemotherapy and Anti-EGFR Antibody May Help Some Colorectal Cancer Patients | Colorectal Cancer | meta-analysis | The pooled objective response rate was 85% (95% CI, 0.78-0.91; I = 58%) and the pooled rate of R0 resection was 42% (95% CI, 0.32-0.53; I = 62%). | Source → |
| Combining two drugs may help some colorectal cancer patients | Colorectal Cancer | preclinical | Vertical inhibition with trametinib and cetuximab induced SD or PR in 74% of analysed models. | Source → |
| Cancer Study Finds Survival Rates for Metastatic Colorectal Cancer Patients | Colorectal Cancer | observational | The median overall survival was 10.4 months, with 6.6 months for patients with right colon cancers and 11.5 months for left colon cancers. | Source → |
| RAS Mutations Emerge in Some Patients on Cetuximab | Leukemia | observational | The subgroup of patients with RAS mutations exhibited significantly inferior progression-free survival (P = 0.002) and overall survival (P = 0.027). | Source → |
| Combining Two Cancer Drugs May Help Some Patients with Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | The 4-month disease control rate was 20%. | Source → |
| Understanding Cetuximab Resistance in Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Understanding Cetuximab Resistance in Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Combining Two Targeted Therapies for Rare Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Bevacizumab plus chemotherapy may be better for some colorectal cancer patients | Colorectal Cancer | observational | Patients treated with bevacizumab-based chemotherapy had a median overall survival of 30.0 months compared to 26.3 months for those treated with cetuximab-based chemotherapy. | Source → |
| Combining Cetuximab with Chemotherapy for Liver Cancer | Colorectal Cancer | phase-2 | The rate of no evidence of disease achieved was 70.1% in the cetuximab group and 41.2% in the control group. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.